Company: INMB
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001213900-25-104141
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 of these unaudited condensed consolidated financial statements.

3

INMUNE BIO INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES
IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER
30, 2024

(In thousands, except share amounts)

(Unaudited)

    Accumulated  

    Additional  
    Other  
       
    Total 

    Common Stock  
    Paid-In  
    Comprehensive  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Capital  
    Income (Loss)  
    Deficit  
    Equity 
  
    Balance as of December 31, 2023 
     17,950,776  
    $18  
    $159,143  
    $(799) 
    $(121,022) 
    $37,340 
  
    Stock-based compensation 
     -  
     -  
     1,779  
     -  
     -  
     1,779 
  
    Gain on foreign currency translation 
     -  
     -  
     -  
     130  
     -  
     130 
  
    Net loss 
     -  
     -  
     -  
     -  
     (11,025) 
     (11,025)
  
    Balance as of March 31, 2024 
     17,950,776  
     18  
     160,922  
     (669) 
     (132,047) 
     28,224 
  
    Stock-based compensation 
     -  
     -  
     2,350  
     -  
     -  
     2,350 
  
    Common stock issued for cash 
     198,364  
     -  
     2,032  
     -  
     -  
     2,032 
  
    Common stock and warrants issued for cash 
     1,557,592  
     2  
     13,463  
     -  
     -  
     13,465 
  
    Loss on foreign currency translation 
     -  
     -